Astria Therapeutics, Inc. (NASDAQ:ATXS) Holdings Decreased by Sio Capital Management LLC

Sio Capital Management LLC lowered its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 1.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 504,887 shares of the biotechnology company’s stock after selling 5,380 shares during the quarter. Astria Therapeutics comprises about 2.2% of Sio Capital Management LLC’s portfolio, making the stock its 16th biggest holding. Sio Capital Management LLC owned 0.89% of Astria Therapeutics worth $5,559,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FMR LLC boosted its position in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after acquiring an additional 480,184 shares during the last quarter. Millennium Management LLC raised its position in shares of Astria Therapeutics by 13.5% during the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after purchasing an additional 218,518 shares during the period. Affinity Asset Advisors LLC increased its position in Astria Therapeutics by 15.4% during the second quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock worth $8,878,000 after buying an additional 130,000 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Astria Therapeutics in the second quarter worth about $6,142,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Up 1.9 %

Astria Therapeutics stock opened at $10.50 on Friday. The business has a 50 day moving average price of $11.18 and a two-hundred day moving average price of $10.62. Astria Therapeutics, Inc. has a 12 month low of $4.50 and a 12 month high of $16.90.

Wall Street Analysts Forecast Growth

ATXS has been the topic of a number of recent analyst reports. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Wedbush restated an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Thursday, November 14th. Finally, Oppenheimer raised their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.